Latest Conference Articles

Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.

Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.

Hisaharu Suzuki, MD, PhD, provides insight on how a handpiece maintains the anterior chamber stability even when occlusion occurs, suggesting its usefulness for a safe and efficient surgery.

Kathryn M. Hatch, MD, details how collagen CXL is evolving with the goals of reducing complications and actually improving visual acuity.

Chuck Hess shares an update on Bausch + Lomb's latest developments in surgical technology, as well as how the company has adapted its operations during the pandemic.

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.

Jonathan D. Shader, DO, CPA, presents a case study involving an uncommon cause of posterior-intermediate uveitis: the black ink used to create a tattoo.

Case study looks at a 90-year-old patient with a sebaceous gland carcinoma with corneal and bulbar conjunctival involvement, but the eyelid was spared.

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.

This announcement was made at the 2021 ASCRS annual meeting.

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Preexisting neutralizing antibodies associated with the inflammatory changes.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.

In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Mohamed Abou Shousha, MD, PhD, and Richard Parrish II, MD, discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Non-invasive ocular blood flow measurement using laser speckle flowgraphy may be a new indicator of shock-related organ damage, investigators report.